Explore our materials

Filters

Results (4380)

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

What is an acceptable BMI | Lee Kaplan, MD, PhD

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Role of Bariatric Surgery - Pre-, During or Post-Transplant | Julie Heimbachx, MD

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Optimizing Immunosuppression | Mohammed Siddiqui

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Panel Discussion

Dmitry Manuilov

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV - D. Manuilov, MD

Douglas Mayers

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Active Site Polymerase Inhibitor Nucleotides (APSINs) - D. Mayers, MD

Matthew McClure

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

STOP Agents - M. McClure, MD

Leigh Felton

BSc, PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Antisense Oligos - L. Felton, BSc, PhD

Luisa Stamm

MD, PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Core Inhibitors (Capsid Assembly Modulators) - L. Stamm, MD, PhD

Stephan Urban

PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Biological Insights Taught by Clinical Responses to Novel Hbv/Hdv Drugs - S. Urban, PhD